These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 25036425)

  • 21. No trip needed for psychedelics to lift mood?
    O'Grady C
    Science; 2023 Jun; 380(6649):999. PubMed ID: 37289868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of central serotonergic mechanisms on head-twitch and backward locomotion induced by hallucinogenic drugs.
    Yamamoto T; Ueki S
    Pharmacol Biochem Behav; 1981 Jan; 14(1):89-95. PubMed ID: 6258178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Return of the lysergamides. Part V: Analytical and behavioural characterization of 1-butanoyl-d-lysergic acid diethylamide (1B-LSD).
    Brandt SD; Kavanagh PV; Westphal F; Stratford A; Elliott SP; Dowling G; Wallach J; Halberstadt AL
    Drug Test Anal; 2019 Aug; 11(8):1122-1133. PubMed ID: 31083768
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT
    Kim K; Che T; Panova O; DiBerto JF; Lyu J; Krumm BE; Wacker D; Robertson MJ; Seven AB; Nichols DE; Shoichet BK; Skiniotis G; Roth BL
    Cell; 2020 Sep; 182(6):1574-1588.e19. PubMed ID: 32946782
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Electrographic and behavioral effects of various hallucinogens in the free cat].
    Rougeul A; Verdeaux J; Letalle A
    Rev Neurol (Paris); 1969 Jun; 120(6):391-4. PubMed ID: 5379317
    [No Abstract]   [Full Text] [Related]  

  • 26. Hallucinogen-like actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats.
    Fantegrossi WE; Harrington AW; Kiessel CL; Eckler JR; Rabin RA; Winter JC; Coop A; Rice KC; Woods JH
    Pharmacol Biochem Behav; 2006 Jan; 83(1):122-9. PubMed ID: 16460788
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacologic Similarities and Differences Among Hallucinogens.
    Waters K
    J Clin Pharmacol; 2021 Aug; 61 Suppl 2():S100-S113. PubMed ID: 34396556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological characterization of the LSD analog N-ethyl-N-cyclopropyl lysergamide (ECPLA).
    Halberstadt AL; Klein LM; Chatha M; Valenzuela LB; Stratford A; Wallach J; Nichols DE; Brandt SD
    Psychopharmacology (Berl); 2019 Feb; 236(2):799-808. PubMed ID: 30298278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD).
    Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD
    Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hallucinogens and Drosophila: linking serotonin receptor activation to behavior.
    Nichols CD; Ronesi J; Pratt W; Sanders-Bush E
    Neuroscience; 2002; 115(3):979-84. PubMed ID: 12435434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Characterization of the head-twitch response induced by hallucinogens in mice: detection of the behavior based on the dynamics of head movement.
    Halberstadt AL; Geyer MA
    Psychopharmacology (Berl); 2013 Jun; 227(4):727-39. PubMed ID: 23407781
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences across sexes on head-twitch behavior and 5-HT
    Jaster AM; Younkin J; Cuddy T; de la Fuente Revenga M; Poklis JL; Dozmorov MG; González-Maeso J
    Neurosci Lett; 2022 Sep; 788():136836. PubMed ID: 35963476
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disrupted integration of sensory stimuli with information about the movement of the body as a mechanism explaining LSD-induced experience.
    Juszczak GR
    Med Hypotheses; 2017 Mar; 100():94-97. PubMed ID: 28236857
    [TBL] [Abstract][Full Text] [Related]  

  • 34. LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
    Marek GJ; Aghajanian GK
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1373-82. PubMed ID: 8819525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Models of psychedelic drug action: modulation of cortical-subcortical circuits.
    Doss MK; Madden MB; Gaddis A; Nebel MB; Griffiths RR; Mathur BN; Barrett FS
    Brain; 2022 Apr; 145(2):441-456. PubMed ID: 34897383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neurophysiological effects of hallucinogens on serotonergic neuronal systems.
    McCall RB
    Neurosci Biobehav Rev; 1982; 6(4):509-14. PubMed ID: 7177511
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonergic hallucinogens as translational models relevant to schizophrenia.
    Halberstadt AL; Geyer MA
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2165-80. PubMed ID: 23942028
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hallucinogens recruit specific cortical 5-HT(2A) receptor-mediated signaling pathways to affect behavior.
    González-Maeso J; Weisstaub NV; Zhou M; Chan P; Ivic L; Ang R; Lira A; Bradley-Moore M; Ge Y; Zhou Q; Sealfon SC; Gingrich JA
    Neuron; 2007 Feb; 53(3):439-52. PubMed ID: 17270739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
    Titeler M; Lyon RA; Glennon RA
    Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The promises and perils of psychedelic pharmacology for psychiatry.
    McClure-Begley TD; Roth BL
    Nat Rev Drug Discov; 2022 Jun; 21(6):463-473. PubMed ID: 35301459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 42.